Suraksha Diagnostic Limited (SURAKSHA) Fair Value & Analysis
Healthcare · IN · Market cap ₹14.2B
Fair value as of: Aug 16, 2026
From 24 valuation models · updated 2 days ago
Fair value updated Aug 16, 2026, revised from ₹123.60 to ₹135.97 (+10.0%) since Aug 8, 2026. Share price +19.1% over the past month.
A solid business, but screening 56% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹169.96). The favourable scenario is already priced in.
- Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (₹77.39 to ₹169.96) leaves room in how you read the outcome.
Price vs Fair Value (20 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 16, 2026.
How to read this chart
20‑month range ₹227.95 – ₹418.65 · fair‑value band ₹77.39 – ₹169.96 · the ₹308.45 price screens above the ₹135.97 fair value. Dashed = 300-day average. As of Aug 16, 2026.
Analysis
Suraksha Diagnostic Limited (SURAKSHA) currently trades at ₹308.45, while our model-based Fair Value estimate is ₹135.97, implying the stock looks roughly 55.9% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Suraksha Diagnostic Limited generated revenue of ₹3.1B at a net margin of 10.4%. Revenue grew 31.2% year over year. It earns a return on equity of 13.8%. Net debt stands at ₹1.0B. Fundamentals as of Aug 16, 2026
Our scenario range runs from ₹77.39 (bear case) to ₹169.96 (bull case); at ₹308.45, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 7% below its 52-week high and 38% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -50% fair-value upside, at -56%, SURAKSHA screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (₹150.36) versus Asset-Based (₹31.50). Highest evidence: Growth DCF (80).
Notify me when SURAKSHA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 48
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, …
Full company description
Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises electrocardiogram, echocardiogram, stress test / treadmill test, wireless holter monitoring, colour doppler, peripheral doppler, and pulmonary function test; gastroenterology, such as upper and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy; and neurology testing services, including electroencephalogram, electromyography, and nerve conduction velocity test. In addition, the company provides dental, physiotherapy, immunology & rheumatology, eye, fetal care, ENT, and speciality clinics, as well as home doctor visit services. The company was founded in 1992 and is based in Kolkata, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Suraksha Diagnostic Limited reported revenue of ₹3.1B in FY2026 versus ₹2.2B in FY2022, a compound +8.6%/yr. Reported net income was ₹322M in FY2026, compounding +11.5%/yr from FY2022.
SURAKSHA screens 56% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 136 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $603.01 | $308.19 | -49% |
| Danaher Corporation DHR | $205.79 | $103.88 | -50% |
| WuXi AppTec Co 2359 | HK$198.90 | HK$157.39 | -21% |
| Lonza Group LONN | CHF 566.20 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $570.58 | $255.77 | -55% |
| Agilent Technologies, Inc A | $148.24 | $61.53 | -58% |
| Waters Corporation WAT | $416.15 | $121.96 | -71% |
| IQVIA Holdings IQV | $236.66 | $132.17 | -44% |
| Illumina, Inc ILMN | $192.91 | $95.51 | -50% |
| Mettler-Toledo International Inc MTD | $1,419 | $615.78 | -57% |
Compare Suraksha Diagnostic Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Suraksha Diagnostic Limited (SURAKSHA) overvalued or undervalued?
What is the fair value of SURAKSHA?
What is the quality score of SURAKSHA?
What is the revenue of Suraksha Diagnostic Limited (SURAKSHA)?
What is the net profit margin of SURAKSHA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Suraksha Diagnostic Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.